| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma |
ACTRN12620000794909: An efficacy study of combined oral doses of glecaprevir/pibrentasvir and sofosbuvir for 16 weeks in hepatitis C patients with documented NS5A resistance who did not respond to previous treatment |
|
|
| Not yet recruiting | 4 | 75 | | | Auckland District Health Board, Auckland District Health Board | Hepatitis C | | | | |
2017-002008-28: A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program |
|
|
| Ongoing | 4 | 50 | Europe | Maviret 100 mg/40 mg tablets, Tablet, Maviret 100 mg/40 mg filmdragerade tabletter glekaprevir/pibrentasvir Maviret 100 mg/40 mg film-coated tablets | Region Skåne, Region Skane | Patients with chronic hepatitis C and without somatic and/or psychiatric contraindications to treatment will be offered participation in the study in a chronological inclusion procedure., Diseases [C] - Virus Diseases [C02] | | | | |
2017-005179-21: Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, uden betydende arvæv i leveren |
|
|
| Terminated | 4 | 227 | Europe | Maviret, Moderiba, Copegus, J05AX, J05AB04, Tablet, Maviret, Moderiba, Copegus | Department of infectious Diseases, Odense University Hospital, Danish regions | Chronic Hepatitis C Kronisk hepatitis C, Chronic Hepatitis C Kronisk leverbetændelse type C, Diseases [C] - Virus Diseases [C02] | | | | |
| Unknown status | 4 | 30 | US | Glecaprevir-pibrentasvir | Id Care, AbbVie | Hepatitis C, Addict Heroin | 09/18 | 03/19 | | |
NCT03627299: Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors |
|
|
| Completed | 4 | 11 | US | 300mg glecaprevir/pibrentasivir 120mg, Mavyret | Johns Hopkins University | End Stage Renal Disease, Hepatitis C | 12/19 | 09/21 | | |
| Completed | 4 | 30 | US | glecaprevir/pibrentasvir treatment, Mavyret treatment | Raymond Chung, AbbVie, University of Pennsylvania, Johns Hopkins University, University of Cincinnati, Weill Medical College of Cornell University, University of Michigan, Northwestern University | Renal Failure Chronic, Hepatitis C | 03/20 | 12/21 | | |
| Completed | 4 | 25 | US | Transplant with HCV positive donor, followed by surveillance and treatment of viremia | NYU Langone Health | Heart Failure | 05/20 | 05/20 | | |
NCT02946034: Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C |
|
|
| Completed | 4 | 10 | US | Viekira Pak ± ribavirin, AbbVie 3D regimen, Mavyret | Massachusetts General Hospital, AbbVie | Chronic Kidney Disease, Chronic Hepatitis C | 09/20 | 09/20 | | |
NCT03623568: Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant |
|
|
| Withdrawn | 4 | 0 | US | glecaprevir/pibrentasvir tablets, Mavyret | Raymond T. Chung, MD | Kidney Failure, Kidney Diseases, Hepatitis C | 12/20 | 04/21 | | |
NCT04614142: Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access |
|
|
| Withdrawn | 4 | 0 | US | Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] | Massachusetts General Hospital | End Stage Renal Disease, Chronic Hepatitis c | 08/21 | 08/21 | | |
ECLIPSE, NCT04235049: Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations |
|
|
| Withdrawn | 4 | 0 | US | Glecaprevir/pibrentasvir | University of Maryland, Baltimore, Merck Sharp & Dohme Corp., Maryland Department of Public Safety and Correctional Services | HCV Infection | 03/22 | 10/24 | | |
NCT03625687: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant |
|
|
| Terminated | 4 | 19 | US | Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks, DAA treatment, Mavyret, Epclusa | Massachusetts General Hospital | Respiratory Failure, Hepatitis C | 04/22 | 04/22 | | |
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication |
|
|
| Completed | 4 | 87 | US | Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI | University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC | Cardiovascular Diseases, Hepatitis C, Hiv | 12/22 | 12/22 | | |
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
|
|
| Recruiting | 4 | 30 | RoW | Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret | Kirby Institute | Hepatitis C | 02/26 | 02/26 | | |
QUICK-CURE, NCT04515797: QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
|
|
| Terminated | 4 | 2 | US | Glecaprevir and Pibrentasvir, Direct Acting Antiviral HCV Treatment, Mavyret | Massachusetts General Hospital | Kidney Failure, Hepatitis C, Kidney Disease, Chronic | 08/23 | 08/23 | | |
NCT04575896: Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
|
|
| Completed | 4 | 10 | US | Glecaprevir/pibrentasvir, Mavyret | Johns Hopkins University | End Stage Renal Disease, Hepatitis C | 11/23 | 12/23 | | |
NCT04508907: A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients |
|
|
| Active, not recruiting | 4 | 200 | US | Mavyret, Zetia | Mayo Clinic | Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection | 11/25 | 11/26 | | |
NCT05582681: HCV Test and Treat Utilizing Simplified HCV Patient Education |
|
|
| Terminated | 4 | 8 | US | Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir, G/P | Weill Medical College of Cornell University, AbbVie | Hepatitis C | 11/24 | 11/24 | | |
2017-002221-37: Six weeks of Glecaprevir/ pibrentasvir for patients with acute HCV infection. Sei settimane di terapia con Glecaprevir/ pibrentasvir per i pazienti con epatite acuta da HCV. |
|
|
| Terminated | 3/4 | 50 | Europe | Glecaprevir/Pibrentasvir, [Glecaprevir/Pibrentasvir], Film-coated tablet, MAVIRET n.AIC 045445018/E | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Abbvie | Acute HCV infection Epatite acuta da HCV, Acute HCV infection Epatite acuta da HCV, Diseases [C] - Virus Diseases [C02] | | | | |
